print_label | resize_label

BRILIQUE™, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

*For physicians in 27 member states of the EU, Norway, Iceland and Liechtenstein

The PLATO trial suggests that for every 91 ACS patients treated with BRILIQUE™ in place of clopidogrel, 1 CV death will be prevented (NNT=91).1

Learn about the pivotal PLATO study

Read a short overview of the efficacy and safety of BRILIQUE™ in patients with Acute Coronary Syndromes.

View a slide kit about the PLATO study

Download full details of the efficacy and safety of BRILIQUE™ compared with that of clopidogrel.

Watch a short video about the PLATO study

Understand the data from the PLATO study, comparing the efficacy and safety of BRILIQUE™ to that of clopidogrel.

1. BRILIQUE Summary of Product Characteristics, 2013.